Spots Global Cancer Trial Database for ibi305
Every month we try and update this database with for ibi305 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Sintilimab Combined With GEMOX ± IBI305 (Bevacizumab Biosimilar) Versus GEMOX in Advanced Intrahepatic Cholangiocarcinoma | NCT05251662 | Intrahepatic Ch... | Sintilimab IBI305 GEMOX | 18 Years - 75 Years | Tianjin Medical University Cancer Institute and Hospital | |
| A Study to Evaluate the Efficacy and Safety of Sintilimab in Combination With IBI305 (Anti-VEGF Monoclonal Antibody) Compared to Sorafenib as the First-Line Treatment for Advanced Hepatocellular Carcinoma. | NCT03794440 | Hepatocellular ... | Sintilimab IBI305 Sorafenib | 18 Years - | Innovent Biologics (Suzhou) Co. Ltd. | |
| Sintilimab Combined With GEMOX ± IBI305 (Bevacizumab Biosimilar) Versus GEMOX in Advanced Intrahepatic Cholangiocarcinoma | NCT05251662 | Intrahepatic Ch... | Sintilimab IBI305 GEMOX | 18 Years - 75 Years | Tianjin Medical University Cancer Institute and Hospital | |
| Sintilimab ± IBI305 Plus Chemotherapy (Pemetrexed + Cisplatin) for EGFRm + Locally Advanced or Metastasis Non-Squamous NSCLC Patients After EGFR-TKI Treatment Failure | NCT03802240 | Non-Squamous No... | Sintilimab IBI305 Pemetrexed Cisplatin Placebo1 Placebo2 | 18 Years - 75 Years | Innovent Biologics (Suzhou) Co. Ltd. | |
| Sintilimab ± IBI305 Plus Chemotherapy (Pemetrexed + Cisplatin) for EGFRm + Locally Advanced or Metastasis Non-Squamous NSCLC Patients After EGFR-TKI Treatment Failure | NCT03802240 | Non-Squamous No... | Sintilimab IBI305 Pemetrexed Cisplatin Placebo1 Placebo2 | 18 Years - 75 Years | Innovent Biologics (Suzhou) Co. Ltd. | |
| A Study to Evaluate the Efficacy and Safety of Sintilimab in Combination With IBI305 (Anti-VEGF Monoclonal Antibody) Compared to Sorafenib as the First-Line Treatment for Advanced Hepatocellular Carcinoma. | NCT03794440 | Hepatocellular ... | Sintilimab IBI305 Sorafenib | 18 Years - | Innovent Biologics (Suzhou) Co. Ltd. | |
| Sintilimab ± IBI305 Plus Chemotherapy (Pemetrexed + Cisplatin) for EGFRm + Locally Advanced or Metastasis Non-Squamous NSCLC Patients After EGFR-TKI Treatment Failure | NCT03802240 | Non-Squamous No... | Sintilimab IBI305 Pemetrexed Cisplatin Placebo1 Placebo2 | 18 Years - 75 Years | Innovent Biologics (Suzhou) Co. Ltd. | |
| A Study to Evaluate the Efficacy and Safety of Sintilimab in Combination With IBI305 (Anti-VEGF Monoclonal Antibody) Compared to Sorafenib as the First-Line Treatment for Advanced Hepatocellular Carcinoma. | NCT03794440 | Hepatocellular ... | Sintilimab IBI305 Sorafenib | 18 Years - | Innovent Biologics (Suzhou) Co. Ltd. | |
| Sintilimab and Chidamide in Combination With or Without IBI305 in Advanced or Metastatic pMMR/MSS Colorectal Carcinoma | NCT04724239 | Advanced Micros... Metastatic Micr... | Sintilimab Chidamide IBI305 | 18 Years - 75 Years | Sun Yat-sen University | |
| Sintilimab and Chidamide in Combination With or Without IBI305 in Advanced or Metastatic pMMR/MSS Colorectal Carcinoma | NCT04724239 | Advanced Micros... Metastatic Micr... | Sintilimab Chidamide IBI305 | 18 Years - 75 Years | Sun Yat-sen University | |
| Sintilimab and Chidamide in Combination With or Without IBI305 in Advanced or Metastatic pMMR/MSS Colorectal Carcinoma | NCT04724239 | Advanced Micros... Metastatic Micr... | Sintilimab Chidamide IBI305 | 18 Years - 75 Years | Sun Yat-sen University |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
